Annals of Vaccines and Immunization

Developing a Vaccine for Human Rhinoviruses

Mini Review | Open Access | Volume 1 | Issue 1

  • 1. Cellular and Molecular Immunology Research Centre, London Metropolitan University and Airways Disease Infection Section, National Heart and Lung Institute, UK
+ Show More - Show Less
Corresponding Authors
McLean GR, Cellular and Molecular Immunology Research Centre, London Metropolitan University, 166-220 Holloway Road, London N7 8DB&Airways Disease Infection Section, National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG, UK, Tel: +442071334070

Rhinoviruses (RV’s) are extremely common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are the major initiator of acute exacerbations of chronic airway diseases. Infections can be life threatening in the latter context however RV-induced common colds have an associated economic cost from loss of productivity due to absence from work or school. There are no appropriate antiviral therapies available and vaccine strategies have failed because of the large number of viral serotypes and the lack of cross-serotype protection generated. Here, approaches past and present for development of a vaccine to these widespread human pathogens are highlighted.


Rhinovirus; Immunity; Vaccine; Mouse model


RMcLean G (2014) Developing a Vaccine for Human Rhinoviruses. Ann Vaccines Immunization 1(1): 1004.



Rhinoviruses (RVs) are a species of human pathogens belonging to the genus enterovirus of the picornaviridae family of viruses [1]. RVs are very small viruses about 30nm in diameter that contain a positive sense ssRNA genome of approximately 7500bp that is surrounded by a protein capsid which is composed of 60 copies of 4 protein subunits that assemble an icosahedron. These structural proteins consist of the externally facing VP1, VP2 and VP3 and internal VP4 which lies at the interface of the capsid and RNA genome [2]. RVs infect and cause disease in all humans but most significantly in those individuals with underlying lung diseases such as asthma or chronic obstructive pulmonary disease, where they are the major precipitants of acute exacerbations [3]. The success of RV’s as human pathogens is due not only to their speed of infection and onward transmission but also to their ability to adapt and change, resulting in the existence of numerous antigenically distinct serotypes. The original definition and numbering of serotypes from 1 to 100 was based on antibody neutralisation properties with polyclonal antisera where little or no cross-serotype neutralization is observed [4]. Antibodies are directed against the outer surface of the RV capsid most commonly to exposed areas of VP1, VP2 and VP3 [5,6]. Regions of the capsid sequences display a high degree of heterogeneity amongst serotypes where there are areas with less than 70% homology within the RV polyproteins (Figure 1)

Figure 1 Schematic diagram of RV polyprotein displaying individual proteins as boxes. The polyprotein is organised into the N terminal proximal  structural proteins (capsid proteins VP4, VP2, VP3 and VP1) followed by the non-structural proteins (P2A, P2B, P2C, P3A, VPg, P3B, Pol) which  are C terminal proximal. Regions with >90% conservation among the RV types A and B are denoted with a black line and regions displaying <70%  conservation are marked with a grey line. The region at the N terminus that corresponds to the VP0 experimental vaccine is marked with a double  line.

Figure 1: Schematic diagram of RV polyprotein displaying individual proteins as boxes. The polyprotein is organised into the N terminal proximal structural proteins (capsid proteins VP4, VP2, VP3 and VP1) followed by the non-structural proteins (P2A, P2B, P2C, P3A, VPg, P3B, Pol) which are C terminal proximal. Regions with >90% conservation among the RV types A and B are denoted with a black line and regions displaying <70% conservation are marked with a grey line. The region at the N terminus that corresponds to the VP0 experimental vaccine is marked with a double line.

[7]. These result in variable surface-exposed immunodominant epitopes that can dictate serotype-specific immune responses. Based on RNA genome sequence analyses, RV’s have now been divided into three groups known as RV types A, B and C [8]and may be further classified by entry receptor usage. Approximately 90% of characterized RV strains (major group) use ICAM-1 as receptors to enter host epithelial cells [9]whereas the minor group exploits members of the Low-Density Lipoprotein (LDL) receptor family[10]. The entry receptor for group C RV’s has yet to be identified due to propagation difficultiesin vitro[11] and it is therefore difficult to pinpoint the exact number of RV serotypes but there may be upwards of 160. The fact that adults experience on average of 2-5 infections and children up to 12 infections per year, when coupled with the lack of cross protective immunity between serotypes ensures that humans can expect a lifetime of RV infections. A broadly cross protective vaccine could alleviate many of these infections and the associated health and economic issues, particularly in those with underlying chronic airways diseases.

Early attempts at RV vaccines

During the late 1960s and early 1970s clinical trials were performed to investigate a common cold vaccine, largely through administration of a formalin inactivated single RV serotype (RV13)[12-17]. This approach was found to provide only minimal protective effects and was abandoned in favour of testing of inactivated multivalent vaccines spanning 10 serotypes [18]. Although these vaccines attempted to address the issue of weak cross-serotype protection induced by monovalent vaccination, they also lost popularity when surprisingly they failed to induce significant cross protection amongst RV serotypes. Table 1

Table 1: Summary of early clinical studies investigating efficacy of RV vaccines

Vaccine Administration Route Findings Reference
Formalin inactivated RV3, RV7, RV10, RV13, RV14, RV18, RV22, RV42, RV43, RV55 (decavalent) intramuscular Minimal homologous and hererologous neutralizing antibody responses Hamory [18]
Formalin inactivated RV13 subcutaneous Homotypic neutralising antibody generated and reduced viral shedding upon homotypic challenge Douglas [17]
Formalin inactivated RV13 intranasal Resistance to homotypic challenge Buscho [16]
Formalin inactivated RV13 intranasal Resistance to homotypic challenge Perkins [14]
Formalin inactivated RV13 Intranasal & intramuscular Protection to homotypic challenge by intranasal immunization & correlated with level of nasal neutralisaing antibody Perkins [15]
Formalin inactivated single strain intranasal Protection to homotypic challenge by intranasal immunization & correlated with level of nasal neutralisaing antibody Mitchison [13]
Live & formalin inactivated single strain Intranasal & intramuscular Increased homotypic antibody responses with live intranasal and inactive intramuscular Doggett [12]

summarises these studies that have been performed in humans using inactivated RV preparations as vaccines. We now know that it is highly likely that inactivation of RV for vaccine studies is unfavourable for the generation of significant cell mediated immune responses and that antibody responses alone that are often generated in such situations are insufficient for broad protection. Formalin treatment was the most common method for RV inactivation although alternative methods such as heat treatment (pasteurisation), low pH and UV treatment are also effective. These methods, whilst largely safe for human application, are likely to destroy many epitopes required for optimal immune responses and therefore can impact negatively on vaccine efficacy by reducing preparation immunogenicity. In addition, another potential reason as to why these prior studies displayed limited success is that there was no evidence indicating that an adjuvant was used to amplify immune responses. The use of adjuvants would most likely have improved vaccine efficacy significantly however, at that time, Alum was the only approved adjuvant for use in humans whilst there are now several others available[19].

Experimental studies in immunised animals (rabbits and mice) began to determine some properties of antibody cross reactivity [20-22] briefly encouraging renewed hope for an RV vaccine as cross-serotype neutralising antibodies were convincingly demonstrated (Table 2).

Table 2: Summary of animal studies investigating RV antibodies after vaccination.

Immunogen & Animal Model Administration Route Findings Reference
Inactivated RV16 Cotton rat intramuscular Generation of cross-serotype neutralizing antibody responses following intranasal challenge Blanco [29]
Recombinant VP0 of RV16 Mouse subcutaneous Generation of cross-serotype neutralizing antibody responses following intranasal challenge Blanco [29]
Inactivated RV1B Mouse subcutaneous Generation of cross-serotype neutralizing antibody responses following intranasal challenge McLean [28]
Recombinant VP1 of RV89 & RV14 Rabbit & mouse subcutaneous Generation of cross-serotype neutralizing antibody responses Edlmayr [24]
VP4 peptides of RV14 Rabbit subcutaneous Generation of cross-serotype neutralizing antibody responses Katpally [23]
VP1 & VP3 peptides of RV14 Rabbit subcutaneous Generation of cross-serotype neutralizing antibody responses McCray [22]
Numerous RV serotypes individually Rabbit intravenous Extensive cross-serotype binding antibody responses Cooney [20]

Despite these positive steps, RV vaccine research studies in the scientific literature then virtually disappeared for over 20 years before further studies in immunised animals with recombinant RV capsid protein subunits and synthetic peptides again proposed possibilities for cross-serotype protective antibodies generation. Here, short conserved regions at the N-terminus of the capsid protein VP4 were identified that elicit cross-serotype protective antibodies [23] and others found that the entire VP1 polypeptide had similar effects [24]. Despite these encouraging studies and the application of modern molecular analyses, the formal demonstration of protective vaccine responses to RV’s in in vivo settings remained elusive largely because of the absence of an in vivo model for RV infections.

Recent approaches using mouse models of human RV infection

The advent of a small animal model of human RV infection [25] has permitted new approaches for RV vaccine development where specific virus challenge following immunisation can be addressed. Previously infection of mouse cells and indeed live mice with human RV’s was not thought possible due to significant sequence differences within the major group entry receptor human ICAM-1[26]and the lack of sustained intracellular viral replication despite minor group RV having the ability to enter via the mouse LDL receptor[27]. Mice transgenic for human ICAM-1 and improved methods for generating high titre RV inoculum have now allowed the intranasal infection of mice with RV’s [25]. Here, RV was shown to replicate and cause acute lung inflammation as well as activating innate immune responses and initiating adaptive immune responses. Immunisation and challenge strategies have subsequently been investigated in this model system, providing a basis for evaluating the immunological correlates of protection to RV’s in vivo. Hyper-immunisation of mice with inactivated RV1B, followed by homologous intranasal challenge generated strong cross-serotype neutralising humoral immune responses which were directed at the capsid protein VP1 [28]. Although these antibody responses were neutralising in vitro, similar to prior experimentation in humans, very little protective effect was observed in vivofurther confirming that the use of inactivated RV preparations as immunogens does not provide the appropriate immunological stimulation that can result in broad RV protection.

Thus a different approach was initiated that focussed on the induction of broadly reactive T cell immunity. Here, a conserved region (VP0) of the RV polyprotein amongst type A and type B strains was identified (Figure 1), the recombinant protein was produced in E coli and used as an immunogen in mice [7]. Recombinant VP0 derived from RV16 was immunogenic in vivo, inducing immunogen and RV-specific antibodies and crossserotypic systemic cellular immune responses. The use of a Th1-promoting adjuvant in combination with VP0 induced crossserotype cellular T lymphocytes producing the Th1 cytokine IFN and improved Th1-associated RV-specific antibody responses. Immunised mice challenged with heterologous RV strains displayed enhanced cross-reactive cellular, increased memory CD4 T cell numbers and stronger humoral immune responses suggesting broad cross-serotype reactivity was obtained with this strategy. Most importantly, VP0 immunisation followed by live RV challenge improved the generation of neutralising antibodies to a variety of RV serotypes and also caused more rapid virus clearancein vivo. VP0 therefore represents a useful candidate for a subunit RV vaccine and may function by generating significant cross-reactive Th1 cells that upon heterologous RV challenge quickly stimulates additional protective immune responses. Further experimentation in this model system of RV infection and translation to humans awaits.

Very recently it has been shown that cotton rats are permissive for RV16 infection and display characteristics similar to the mouse RV infection model [29]. Interestingly, in this model prior immunisation with inactivated RV via the intramuscular route but not by the intranasal route produced significant neutralising antibody responses and reduced the viral load in the lungs upon homotypic challenge, confirming findings in the mouse model [7,28]. In further experiments both prophylactic antibody administration and maternal immunity transfer to neonates were both protective although heterotypic responses were not evaluated. The use of this model system in addition to the mouse model will complement human studies and hopefully aid in the identification and development of RV vaccines.


Attempts to produce a protective vaccine to RV’s have failed due to the large number of antigenically distinct serotypes and the lack of a suitable small animal model of infection to test candidates in. The recent discovery of a previously unrecognised clade of RV’s has complicated this further. Nevertheless, studies in immunised animals have demonstrated that significant crossserotype protection is possible. With the advent of small animal immunisation and challenge models, suitable vaccine candidates can now be evaluated thoroughly before translation to humans (Table 2). The quest for a RV vaccine now seems somewhat less forlorn than it did a decade ago.


1. Waman VP, Kolekar PS, Kale MM, Kulkarni-Kale U. Population structure and evolution of Rhinoviruses. See comment in PubMed Commons below PLoS One. 2014; 9: e88981.

2. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. See comment in PubMed Commons below Nature. 1985; 317: 145-153.

3. Greenberg SB. Rhinovirus and coronavirus infections. See comment in PubMed Commons below Semin Respir Crit Care Med. 2007; 28: 182-192.

4. Conant RM, Hamparian VV. Rhinoviruses: basis for a numbering system. II. Serologic characterization of prototype strains. See comment in PubMed Commons below J Immunol. 1968; 100: 114-119.

5. Sherry B, Mosser AG, Colonno RJ, Rueckert RR. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. See comment in PubMed Commons below J Virol. 1986; 57: 246-257.

6. Appleyard G, Russell SM, Clarke BE, Speller SA, Trowbridge M, Vadolas J. Neutralization epitopes of human rhinovirus type 2. See comment in PubMed Commons below J Gen Virol. 1990; 71 : 1275-1282.

7. Glanville N, McLean GR, Guy B, Lecouturier V, Berry C, Girerd Y,  Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. See comment in PubMed Commons below PLoS Pathog. 2013; 9: e1003669.

8. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. See comment in PubMed Commons below Science. 2009; 324: 55-59.

9. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, et al. The major human rhinovirus receptor is ICAM-1. See comment in PubMed Commons below Cell. 1989; 56: 839-847.

10. Hofer F, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. See comment in PubMed Commons below Proc Natl Acad Sci U S A. 1994; 91: 1839-1842.

11. Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. See comment in PubMed Commons below Nat Med. 2011; 17: 627-632.

12. Doggett JE, Bynoe ML, Tyrrell DA. Some attempts to produce an experimental vaccine with rhinoviruses. See comment in PubMed Commons below Br Med J. 1963; 1: 34-36.

13. Mitchison DA. Prevention of Colds by Vaccination Against a Rhinovirus: A Report by the Scientific Committee on common cold vaccines. See comment in PubMed Commons below Br Med J. 1965; 1: 1344-1349.

14. Perkins JC, Tucker DN, Knopf HL, Wenzel RP, Kapikian AZ, Chanock RM. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. See comment in PubMed Commons below Am J Epidemiol. 1969; 90: 519- 526.

15. Perkins JC, Tucker DN, Knope HL, Wenzel RP, Hornick RB, Kapikian AZ, et al. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. See comment in PubMed Commons below Am J Epidemiol. 1969; 90: 319-326.

16. Buscho RF, Perkins JC, Knopf HL, Kapikian AZ, Chanock RM. Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine. J Immunol. 1972; 108: 169-177.

17. Douglas RG Jr, Couch RB. Parenteral inactivated rhinovirus vaccine: minimal protective effect. See comment in PubMed Commons below Proc Soc Exp Biol Med. 1972; 139: 899-902.

18. Hamory BH, Hamparian VV, Conant RM, Gwaltney JM Jr. Human responses to two decavalent rhinovirus vaccines. See comment in PubMed Commons below J Infect Dis. 1975; 132: 623-629.

19. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty first century society. Nat Rev Immunol. 2011; 11: 865-872.

20. Cooney MK, Wise JA, Kenny GE, Fox JP. Broad antigenic relationships among rhinovirus serotypes revealed by cross-immunization of rabbits with different serotypes. See comment in PubMed Commons below J Immunol. 1975; 114: 635-639.

21. Fox JP. Is a rhinovirus vaccine possible? See comment in PubMed Commons below Am J Epidemiol. 1976; 103: 345-354.

22. McCray J, Werner G. Different rhinovirus serotypes neutralized by antipeptide antibodies. See comment in PubMed Commons below Nature. 1987; 329: 736-738.

23. Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. See comment in PubMed Commons below J Virol. 2009; 83: 7040-7048.

24. Edlmayr J, Niespodziana K, Popow-Kraupp T, Krzyzanek V, FockeTejkl M, Blaas D, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. See comment in PubMed Commons below Eur Respir J. 2011; 37: 44-52.

25. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. See comment in PubMed Commons below Nat Med. 2008; 14: 199-204.

26. Register RB, Uncapher CR, Naylor AM, Lineberger DW, Colonno RJ. Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding. See comment in PubMed Commons below J Virol. 1991; 65: 6589-6596.

27. Yin FH, Lomax NB. Establishment of a mouse model for human rhinovirus infection. See comment in PubMed Commons below J Gen Virol. 1986; 67 : 2335-2340.

28. McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. See comment in PubMed Commons below Antiviral Res. 2012; 95: 193-201.

29. Blanco JCG, Core S, Pletneva LM, March TH, Boukhvalova MS, Adriana E Kajon. Prophylactic antibody treatment and intramuscular immunization reduce infectious human rhinovirus 16 load in the lower respiratory tract of challenged cotton rats. Trials in Vaccinology. 2014; 3: 52-60.

RMcLean G (2014) Developing a Vaccine for Human Rhinoviruses. Ann Vaccines Immunization 1(1): 1004.

Received : 01 Jun 2014
Accepted : 26 Jun 2014
Published : 01 Jul 2014
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X